hVIVO (LON:HVO) Stock Price Passes Above 50 Day Moving Average - Should You Sell?

Key Points

• hVIVO plc shares have surpassed their 50-day moving average of GBX 10.46, indicating positive trading momentum, with the stock last trading at GBX 10.25.
• Analysts from Shore Capital and Peel Hunt have issued target prices of GBX 35 and GBX 21, respectively, while maintaining a "buy" and "add" rating on the stock.
• hVIVO plc specializes in human challenge clinical trials for vaccine and antiviral testing, serving various pharmaceutical and governmental clients with a market capitalization of £77.83 million.

Shares of hVIVO plc (LON:HVO - Get Free Report) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 10.46 ($0.14) and traded as high as GBX 10.50 ($0.14). hVIVO shares last traded at GBX 10.25 ($0.14), with a volume of 1,339,657 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on HVO shares. Peel Hunt reiterated an "add" rating and issued a GBX 21 ($0.28) price objective on shares of hVIVO in a research report on Tuesday, July 29th. Shore Capital reiterated a "buy" rating and set a GBX 35 ($0.47) price target on shares of hVIVO in a research report on Tuesday, July 22nd.

hVIVO Stock Performance

The stock's 50 day moving average is GBX 10.51 and its two-hundred day moving average is GBX 14.48. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The stock has a market cap of £77.13 million, a price-to-earnings ratio of 4.50 and a beta of 0.97.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.